Gore Acquires Intellectual Property of NMT Medical

October 19, 2011—Gore & Associates (Flagstaff, AZ) announced it has purchased the assets and intellectual property of NMT Medical, Inc. (Boston, MA), including the data related to CLOSURE I. The study data were acquired with the rest of the NMT assets, but the transaction did not transfer any liabilities or regulatory obligations of NMT.

CLOSURE I was a prospective, multicenter, randomized, controlled trial of patent foramen ovale (PFO) closure with NMT's StarFlex device versus best medical therapy for the prevention of recurrent stroke and/or transient ischemic attack (TIA) in patients with cryptogenic stroke/TIA and PFO. The acquisition came after NMT ceased operations earlier this year, advised Gore & Associates.

On November 15, 2010, Anthony J. Furlan, MD, presented late-breaking clinical trial results from CLOSURE I at the American Heart Association's (AHA) Scientific Sessions 2010 in Chicago. As reported in Cardiac Interventions Today, the CLOSURE trial found that a transcatheter procedure for PFO closure appears to be no more effective than drug therapy in preventing recurrent stroke.